🇺🇸 FDA
Patent

US 11666602

Treatment of pulmonary arterial hypertension with mesenchymal stem cells

granted A61KA61K2035/124A61K31/192

Quick answer

US patent 11666602 (Treatment of pulmonary arterial hypertension with mesenchymal stem cells) held by United Therapeutics Corporation expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2035/124, A61K31/192, A61K31/5585, A61K35/15